Abstract
In humans the HIV infection results in a chronic disease with a permanent fight between factors controlling HIV and the escape of the virus. Fromthese control mechanisms the present review summarizes the role betwen complement and autoantibodies; the competition of complement and anti-HIV antibodies for binding sites, the role of mannan-binding lectin in the susceptibility to and in the survival after HIV infection, the contribution of complement-dependent enhancing type antibodies to the clinical progression of HIV disease as well as the changing pattern of some autoantibodies (mimicking MHC class II molecules, anti-heat shock protein 60 antibodies and anti-C1q antibodies) which were found to correlate to immunological and clinical parameters.
Similar content being viewed by others
References
Banapour B, Sernatinger J, and Levy JA: The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 152:268–271, 1986.
Bartholomew RM, Esser AF, and Müller-Eberhard HJ: Lysis of oncornaviruses by human serum. J Exp Med 147:844–853, 1978.
Bartz SR, Pauza CD, Ivanyi J, et al: An Hsp60 related protein is associated with purified HIV and SIV. J Med Primatol 23:151–154, 1994.
Denner J, Norley S, and Kurth R: The immunosuppressive pep- tide of HIV-1: functional domains and immune response in AIDS patients. AIDS 8:1063–1072, 1994.
Ebenhichler CF, Thielens NM, Vornhagen R, et al: Human immunodeficiency virus type-1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174:1417–1424, 1991.
El Jarrah F, Hidvégi T, Ujhelyi E, et al: Complement activation decreases the ability of HIV transmembrane envelope protein to bind to specific antibody. AIDS 6:1050–1051, 1992.
Elsaghier A, Pranter C, Bothamley G, et al: Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Clin Exp Immunol 89: 305–309, 1992.
Ezekowitz RA, Kuhlman M, Groopman JE, and Byrn RA: A human serum mannose-binding protein inhibits in vitro infection by human immunodeficiency virus. J Exp Med 169:185- 196, 1989.
Frank I, Stoiber H, Godar S, et al: Acquisition of host cell-sur-face-derived molecules by HIV-1. AIDS 10: 1611–1620, 1996.
Füst G, Ujhelyi E, Hidvégi T, et al: The complement system in HIV disease. Immunol Invest 20: 231–241, 1991.
Füst G, Prohászka Z, Hidvégi T, et al: Competition of comple- ment proteins and specific antibodies for binding to HIV-1 envelope antigens. Acta Microbiol Immunol Hung 41:Suppl. 27–31, 1994.
Füst G, Tóth DF, Kiss J, et al: Neutralizing and enhancing anti- bodies measured in complement-restored serum samples from HIV-1 infected individuals correlate with immunosuppression and disease. AIDS 8: 603–609, 1994.
Füst G: Enhancing antibodies in HIV-1 infection. Parasitology (in press) 1997.
Garred P, Madsen HO, Hoffmann B, and Svejgard A: Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. The Lancet 349:236–240, 1997.
Gnann Jr.JW, Nelson JA, and Oldstone BA: Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 61:2639–2641, 1987.
Haurum JS, Thiel S, Jones IM, et al: Complement activation upon binding of mannan-binding protein to HIV envelope gly-coproteins. AIDS 7:1307–1313, 1993.
Hidvégi T, Prohászka Z, Ujhelyi E, et al: Studies on the mecha- nism of complement-mediated inhibition of antibody binding to gp41. Clin Exp Immunol 94:490–493, 1993.
Holmskov U, Malhotra R, Sim RB, and Jensenius JC: Collectins: collagenous C-type lectins of the innate immune defense system. Immunology Today 15:67–73, 1994.
Hoshino H, Tanaka H, Miwa M, and Okada H: Human T-cell leukemia virus is not lysed by human serum. Nature 310:324- 325, 1984.
June RA, Schade SZ, Bankowski MJ, et al: Complement and antibody mediate enhancement of HIV infeciton by increasing virus binding and provirus formation. AIDS 5:269–274, 1991.
Kieber-Emmons T, Jameson BA, and Morrow WJW: The gp120- CD4 interface: structural, immunological and pathological considerations. Biochem Biophys Acta 989:281, 1989.
Lund O, Hansen J, Sorensen AM, et al: Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 69:2393–2400, 1995.
Montefiori DC, Robinson, WE, Jr,Hirsch, VM, et al: Antibodydependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol 64:113–119, 1990.
Montefiori DC, Lefkowitz LB, Keller RE, et al: Absence of clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1 infected individuals. AIDS 5:513–517, 1991.
Montefiori DC, Pantaleo G, Fink LM, et al: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J Infect Dis 173:60–67, 1996.
Nielsen SL, Andersen PL, Koch C, et al: The level of serum opsonin, mannan-binding protein in HIV-1 antibody positive patients. Clin Exp Immunol 100:219–222, 1995.
Perelson AS, Neumann AU, Markovitz M, et al: HIV-1 dinamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582–1586, 1996.
Prohászka Z, Hidvégi T, Ujhelyi E, et al: Interaction of comple- ment and specific antibodies with the extenal glycoprotein 120 of HIV-1. Immunology 85:184–189, 1995.
Prohászka Z, Bánhegyi D, Ujhelyi E, et al: Antibodies against 60kD heat shock proteins in human immunodeficiency virus infeciton.. Ann NY Acad Sci, 1997. (accepted for publication)
Prohászka Z, Nemes J, Hidvégi T, et al: Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS 11:949–958, 1997.
Prohászka Z, Thiel S, Ujhelyi E, et al: Mannan-binding lectin (MBL) serum concentrations in HIV infected patients are influenced by the stage of disease. Immunol Lett 58:171–175, 1997.
Ratner L, Haseltine W, Patarca R, et al: Complete nucleotide sequence of the AIDS-virus, HTLV-III. Nature 313:277, 1985.
Robinson WE, Jr,Montefiori DC, Gillespie DH, and Michell WM: Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA synthesis and infectious virus release. J AIDS 2:33- 42, 1989.
Robinson WE, Jr,Montefiori DC, Mitchell WM, et al: Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proc Natl Acad Sci USA 86:4710–4714, 1989.
Senaldi G, Davies ET, Mahalingam M. et al: Circulating levels of mannose binding protein in human imunodeficiency virus infection. J Infect 31:145–148, 1995.
Sölder BM, Schulz TE, Hengster P, et al: HIV and HIV infected cells differentially activate the human complement system independent of antibody. Immunol Lett 22:135–146, 1989.
Spear GT, Takefman DM, Sullivan BL, et al: Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 67:53–59, 1993.
Stoiber H, Clivio A, and Dierich MP: Role of complement in HIV infection. Ann Rev Immunol 15:649–674, 1997.
Stoiber H, Thielens NM, Ebenbichler C, et al: The envelope glycoprotein gp120 of HIV-1 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 24:294–300, 1994.
Süsal C, Daniel V, and Opelz G: Does AIDS emerge from a dis- equilibrium between two complementary groups of moleculaes that mimic the MHC? Immunology Today 17:114–119, 1996.
Süsal C, Kirschfink M, Kröpelin M, et al: Complement activa- tion by recombinant HIV-1 glycoprotein gp120. J Immunol 152:6028–6034, 1994
Thiel S: Mannan-binding protein, a complement activating animal lectin. Immunopharmacology 24:91–99, 1992.
Thielens NM, Bally IM, Ebenbichler CF, et al: Further charac- terization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J Immunol 151:6583–6592, 1993.
Tóth DF, Bánhegyi D, Szabó J, et al: Complement-mediated antibody-dependent enhancement of HIV infection correlates to viral load and predicts progression of HIV disease.(submitted to AIDS, 1997).
Tóth DF, Süsal C, Ujhelyi E, et al: Comparative study of autoan- tibodies that are associated with disease progression in HIV disease. Immunol Lett 41:33–36, 1994.
Tóth DF, Szabó B, Ujhelyi E, et al: Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS 5:263–268, 1991.
Turner MW: Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunology Today 17:532–540, 1996.
Welsh RM, Cooper NR, Jensen FC, and Oldstone MBA: Human serum lyses RNA tumor viruses. Nature 257:612–614, 1975.
Xu JY, Gorny MK, Palker T, et al: Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 65:4832–4838, 1991.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
ProhÁszka, Z., TÓth, F.D., BÁnhegyi, D. et al. Role of complement and antibodies in the control and facilitation of HIV disease. Pathol. Oncol. Res. 3, 296–302 (1997). https://doi.org/10.1007/BF02904290
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02904290